Date:5/6/2009

(1) As adjusted resulting from the adoption of APB 14-1, as of January 1, 2009. (2) Each of the "proforma net income" and "proforma net income per share" (i) are measures of performance that are not required by, or presented in accordance with, GAAP; (ii) should not be considered as alternatives to net income or any other performance measures derived in accordance with GAAP; and (iii) should not be considered in isolation or as a substitute for analysis of GAAP results. Kendle International Inc. Selected Balance Sheet and Other Information (In thousands) (Unaudited) Selected Balance Sheet Information: March 31, December 31, 2009 2008 (As Adjusted (1)) Cash, cash equivalents and marketable securities (including restricted cash) $56,001 $36,053 Receivables, net of advance billings 61,180 63,410 Convertible notes 173,601 171,848 Net Services Revenues by Geographic Region: Three Months Ended March 31 2009 2008 North America 53% 46% Europe 33% 42% Latin America 11% 7% Asia-Pacific 3% 5% Segment Information: Three Months Ended
'/>"/>

SOURCE Kendle International Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
2. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
3. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
4. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
5. Kendle to Present at the UBS Global Life Sciences Conference
6. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
7. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
8. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. Kendle to Present at the Wachovia 2008 Healthcare Conference
11. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality